Source comparison
MT-1 vs MT-2: Structural Differences, Receptor Selectivity, and Side Effect Profiles
MT-1 and MT-2 are both synthetic analogs of α-MSH, but their receptor binding profiles and adverse event patterns diverge significantly. MT-1 (also called afamelanotide in pharmaceutical contexts) is a linear tridecapeptide with high selectivity for MC1R. MT-2
This comparison does not assign a generated winner or score.
- MT-1 and MT-2 are both synthetic analogs of α-MSH, but their receptor binding profiles and adverse event patterns diverge significantly. MT-1 (also called afamelanotide in pharmaceutical contexts) is a linear tridecapeptide with high selectivity for MC1R. MT-2, by contrast, is a cyclic heptapeptide with broad agonist activity across MC1R, MC3R, MC4R, and MC5R. This structural difference. Specifically the cyclization and truncation in MT-2. Expands its receptor promiscuity but introduces side effects not observed with MT-1.
- The most clinically significant difference is MC4R activation. MC4R is expressed in the hypothalamus and regulates satiety signaling, energy expenditure, and erectile function. MT-2's agonism of MC4R produces appetite suppression and spontaneous erections in male subjects. Effects documented in early-phase trials and widely reported in non-clinical use. MT-1 does not produce these effects at physiological doses because its binding affinity for MC4R is approximately 1000-fold lower than for MC1R. For research applications focused strictly on melanogenesis and photoprotection, this selectivity is desirable.
- Nausea is the most common adverse event with both peptides, occurring in approximately 20–35% of subjects during dose escalation. The mechanism is thought to involve transient MC4R stimulation in the area postrema (the brainstem's chemoreceptor trigger zone), although nausea incidence is lower with MT-1 than MT-2. Flushing and mild gastrointestinal discomfort have also been reported. Spontaneous penile erections. The signature MT-2 side effect. Occur in fewer than 5% of MT-1 subjects and only at supra-physiological doses.
- Another key distinction: melanoma risk perception. Both peptides have been scrutinized for their potential to stimulate existing melanocytic lesions. A 2016 systematic review published in Photodermatology, Photoimmunology & Photomedicine concluded that MT-1 (afamelanotide) did not increase melanoma incidence in long-term observational studies of erythropoietic protoporphyria patients who received the peptide as an FDA-approved implant (Scenesse). MT-2, which has never been approved for human use, lacks comparable long-term safety data. Critically, neither peptide has been shown to initiate melanoma. The theoretical concern is progression of pre-existing dysplastic nevi, not de novo carcinogenesis.
- Researchers comparing the two peptides often select Melanotan 1 for studies prioritizing receptor selectivity and minimal off-target effects. MT-2 remains popular in non-clinical contexts due to its faster onset and lower per-dose cost, but those advantages come with increased side effect burden.